Drug industry analysts in the USA are taking the rising prices ofpharmaceutical company shares as "par for the course," given a broad stock market advance. The market seems to be going through a rotation, said Hemant Shah of HKS & Co, who noted that "one day it's oil stocks and the next it's drug stocks."
Steve Scala of Cowen & Co, who was quoted in Business Week as saying that the supercharged environment for the drug sector is not going to continue, noted that, at present, the whole group is "flying without any specific reason."
Still, the drug group's recent performance has been partly attributable to the continued expansion in the overall US stock market, moderate underlying growth in the general economy and rising drug stock earnings forecasts, according Kenneth Kulju of UBS Securities. He feels that the US economic outlook will support another solid year of relative performance for the sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze